BR0312140A - Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes - Google Patents
Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazesInfo
- Publication number
- BR0312140A BR0312140A BR0312140-2A BR0312140A BR0312140A BR 0312140 A BR0312140 A BR 0312140A BR 0312140 A BR0312140 A BR 0312140A BR 0312140 A BR0312140 A BR 0312140A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted
- alpha
- estrogen
- well
- selectively effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0055—Estrane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"ESTRATRIENOS 9-ALFA-SUBSTITUìDOS COMO ESTROGêNIOS SELETIVAMENTE EFICAZES". A presente invenção refere-se a novos estratrienos 9a-substituídos da fórmula geral (I), na qual R3, R7, R7<39>, R13, R16 bem como R17 e R17<198> têm os significados indicados na descrição bem como R9 representa um radical alquenila em cadeia linear ou ramificada, eventualmente parcial ou totalmente halogenado com 2 até 6 átomos de carbono, um radical etinila ou prop-1-inila, como substâncias ativas farmacêuticas, que in vitro apresentam uma maior afinidade corn preparações do receptor de estrogênio de próstata de rato do que com preparações do receptor de estrogênio de útero de rato fêmea e in vivo apresenta de preferência, um efeito preferencial no ovário em comparação com o útero, sua preparação, sua aplicação terapêutica e formas de administração farmacêuticas, que contêm os novos compostos. A invenção descreve além disso, a aplicação destes compostos para o tratamento de doenças e estados devido a deficiência de estrogênio.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10226326A DE10226326A1 (de) | 2002-06-11 | 2002-06-11 | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
PCT/EP2003/006172 WO2003104253A2 (de) | 2002-06-11 | 2003-06-11 | 9-alpha-substituierte estratriene als selektiv wirksame estrogene |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0312140A true BR0312140A (pt) | 2005-04-05 |
Family
ID=29723144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0312140-2A BR0312140A (pt) | 2002-06-11 | 2003-06-11 | Estratrienos 9-alfa-substituìdos como estrogênios seletivamente eficazes |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP1517914B1 (pt) |
JP (1) | JP4615998B2 (pt) |
KR (1) | KR101006612B1 (pt) |
CN (1) | CN1293090C (pt) |
AR (1) | AR040188A1 (pt) |
AT (1) | ATE303397T1 (pt) |
AU (1) | AU2003242683B9 (pt) |
BR (1) | BR0312140A (pt) |
CA (1) | CA2486495C (pt) |
CR (1) | CR10289A (pt) |
CU (1) | CU23414B7 (pt) |
DE (2) | DE10226326A1 (pt) |
DK (1) | DK1517914T3 (pt) |
EA (1) | EA008442B1 (pt) |
EC (1) | ECSP055530A (pt) |
ES (1) | ES2248770T3 (pt) |
HK (1) | HK1081203A1 (pt) |
HR (1) | HRP20050009B1 (pt) |
IL (1) | IL165321A (pt) |
MX (1) | MXPA04012491A (pt) |
NO (1) | NO329563B1 (pt) |
PE (1) | PE20040613A1 (pt) |
PL (1) | PL209910B1 (pt) |
RS (1) | RS50878B (pt) |
TW (1) | TWI286140B (pt) |
UA (1) | UA78062C2 (pt) |
UY (1) | UY27844A1 (pt) |
WO (1) | WO2003104253A2 (pt) |
ZA (1) | ZA200500217B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10027887A1 (de) | 2000-05-31 | 2001-12-13 | Jenapharm Gmbh | Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
ES2307064T3 (es) * | 2003-11-26 | 2008-11-16 | Bayer Schering Pharma Aktiengesellschaft | Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol. |
US7534780B2 (en) | 2004-05-21 | 2009-05-19 | Bayer Schering Pharma Aktiengesellschaft | Estradiol prodrugs |
DE102005057224A1 (de) * | 2005-11-29 | 2007-05-31 | Bayer Schering Pharma Ag | Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
MX2010008945A (es) * | 2008-02-13 | 2010-09-07 | Bayer Schering Pharma Ag | Sistema de administracion de drogas con efecto estabilizante. |
EP2143432A1 (en) | 2008-07-11 | 2010-01-13 | Bayer Schering Pharma AG | 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer |
CA2744127A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
AU2015308987B2 (en) | 2014-08-26 | 2021-02-18 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2336432A1 (de) * | 1973-07-13 | 1975-01-30 | Schering Ag | 3.17.18-trihydroxy-1.3.5(10)-oestratriene |
US6154158A (en) * | 1998-06-30 | 2000-11-28 | Qualcomm Incorporated | Digital-to-analog converter D.C. offset correction comparing converter input and output signals |
DE19906159A1 (de) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-Hydroxyestratriene als selektiv wirksame Estrogene |
DK1226155T3 (da) * | 1999-11-02 | 2007-09-10 | Bayer Schering Pharma Ag | 18-nor-steroider som selektivt virksomme östrogener |
CZ20023382A3 (cs) * | 2000-04-12 | 2003-02-12 | Schering Aktiengesellschaft | Substituované estratrieny jako selektivně účinné estrogeny |
-
2002
- 2002-06-11 DE DE10226326A patent/DE10226326A1/de not_active Ceased
-
2003
- 2003-06-10 PE PE2003000575A patent/PE20040613A1/es not_active Application Discontinuation
- 2003-06-11 UY UY27844A patent/UY27844A1/es not_active Application Discontinuation
- 2003-06-11 CN CNB038135027A patent/CN1293090C/zh not_active Expired - Fee Related
- 2003-06-11 CA CA2486495A patent/CA2486495C/en not_active Expired - Fee Related
- 2003-06-11 EA EA200401544A patent/EA008442B1/ru not_active IP Right Cessation
- 2003-06-11 ES ES03757065T patent/ES2248770T3/es not_active Expired - Lifetime
- 2003-06-11 EP EP03757065A patent/EP1517914B1/de not_active Expired - Lifetime
- 2003-06-11 WO PCT/EP2003/006172 patent/WO2003104253A2/de active IP Right Grant
- 2003-06-11 PL PL373090A patent/PL209910B1/pl not_active IP Right Cessation
- 2003-06-11 AU AU2003242683A patent/AU2003242683B9/en not_active Ceased
- 2003-06-11 TW TW092115863A patent/TWI286140B/zh not_active IP Right Cessation
- 2003-06-11 DE DE50301116T patent/DE50301116D1/de not_active Expired - Lifetime
- 2003-06-11 BR BR0312140-2A patent/BR0312140A/pt not_active IP Right Cessation
- 2003-06-11 AT AT03757065T patent/ATE303397T1/de active
- 2003-06-11 AR ARP030102079A patent/AR040188A1/es active IP Right Grant
- 2003-06-11 RS YUP-1070/04A patent/RS50878B/sr unknown
- 2003-06-11 DK DK03757065T patent/DK1517914T3/da active
- 2003-06-11 KR KR1020047020133A patent/KR101006612B1/ko not_active IP Right Cessation
- 2003-06-11 MX MXPA04012491A patent/MXPA04012491A/es active IP Right Grant
- 2003-06-11 JP JP2004511321A patent/JP4615998B2/ja not_active Expired - Fee Related
- 2003-11-06 UA UAA200500212A patent/UA78062C2/uk unknown
-
2004
- 2004-11-22 IL IL165321A patent/IL165321A/en not_active IP Right Cessation
- 2004-12-10 CU CU20040282A patent/CU23414B7/es not_active IP Right Cessation
-
2005
- 2005-01-05 HR HRP20050009AA patent/HRP20050009B1/hr not_active IP Right Cessation
- 2005-01-10 NO NO20050127A patent/NO329563B1/no not_active IP Right Cessation
- 2005-01-10 EC EC2005005530A patent/ECSP055530A/es unknown
-
2006
- 2006-01-10 ZA ZA200500217A patent/ZA200500217B/en unknown
- 2006-01-27 HK HK06101276A patent/HK1081203A1/xx not_active IP Right Cessation
-
2008
- 2008-09-16 CR CR10289A patent/CR10289A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0109983A (pt) | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes | |
ES2278925T3 (es) | Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal. | |
Darmani et al. | The effects of BIS-GMA and TEG-DMA on female mouse fertility | |
NO20060200L (no) | Farmasoytisk formulering for prevensjons- og hormonerstatningsterapier | |
AR035564A1 (es) | Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos | |
BRPI0416700A (pt) | métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit | |
ECSP055530A (es) | Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva | |
BR0114665A (pt) | Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio | |
BR0008076A (pt) | 16-hidroxiestratrienos como estrogênios de efeito seletivo | |
Balfour et al. | Transdermal estradiol: a review of its pharmacological profile, and therapeutic potential in the prevention of postmenopausal osteoporosis | |
DK1226155T3 (da) | 18-nor-steroider som selektivt virksomme östrogener | |
EA201000097A1 (ru) | 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов | |
Oropeza et al. | Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract | |
ATE263164T1 (de) | Bentzothiophene | |
Seeger et al. | Calcium antagonistic effect of 17α-estradiol derivatives: in vitro examinations | |
BR0116127A (pt) | Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina | |
KR20080072087A (ko) | Er-베타 선택적 물질의 전구약물, 그의 제조 방법 및그것을 포함하는 제약 조성물 | |
UY26967A1 (es) | Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) |
|
B25D | Requested change of name of applicant approved |
Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE) |
|
B25A | Requested transfer of rights approved |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |